SARS-CoV-2 mRNA Vaccination Observed to Potentiate Cancer Immunotherapy Response

The efficacy of immune checkpoint blockade (ICI) in patients with cancer is often limited by an immunosuppressive tumor microenvironment and a lack of tumor antigens, establishing a crucial need for agents to overcome these restrictions. Personalized mRNA vaccines are a promising yet complex and time-intensive approach. Case reports of patients with cancer whose tumors regressed after SARS-CoV-2 mRNA vaccination have posed the question of the influence of non-tumor related vaccines on ICI response. Grippin, Marconi, Copling, Li, and colleagues observed a significant increase in overall survival in patients with non–small cell lung cancer or melanoma who received COVID-19 mRNA vaccination within 100 days of initiation of ICI. Interestingly, such an increase in survival could not be observed in patients who received chemotherapy, nor with vaccines against pneumonia or influenza. In tumor-bearing mice, combining ICI with COVID mRNA vaccination enhanced tumor control, which was dependent on a functional type I IFN response. The increase in T helper 1 chemokines was accompanied by elevated myeloid cell activation in lymphoid organs and the tumor. Moreover, antigen presentation was enriched, resulting in an expansion of tumor-reactive T cells. Intriguingly, other mRNA species elicited similar effects, indicating a role for the mRNA itself as a potential driver of antitumor activity. In healthy volunteers, COVID-19 vaccines induced similar changes in the cytokine profile and elevated levels of PD-L1 on circulating myeloid cells were identified. Similarly, patients with cancer who received COVID-19 mRNA vaccines showed elevated PD-L1 levels within their tumors, including patients whose tumors were classified as immunologically cold. This suggests a model whereby mRNA vaccines induce a surge in cytokines, driving first the activation of antigen-presenting cells and subsequently the T-cell compartment. Upregulation of PD-L1 serves as a counterstrategy to evade this attack, and combination with checkpoint blockade hence induces potent responses. The findings define a potentially important role for mRNA vaccines in sensitizing immunologically cold tumors to immunotherapy, while the detailed mechanism of activation requires further investigation.Grippin AJ, Marconi C, Copling S, Li N, Braun C, Woody C, et al. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature 2025;647:488–97.Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at https://aacrjournals.org/cdnews.